Log In
BCIQ
Print this Print this
 

anagrelide CR (GALE-401)

  Manage Alerts
Collapse Summary General Information
Company Galena Biopharma Inc.
DescriptionControlled-release formulation of anagrelide
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$30.0M

$1.6M

$3.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/13/2014

$30.0M

$1.6M

$3.0M

Get a free BioCentury trial today